S Ramanathan1,2,3, C Fraser4, S R Curnow5, M Ghaly6, R J Leventer7, J Lechner-Scott8,9, A Henderson3,10, S Reddel11,12, R C Dale1,2,11,13, F Brilot1,2,11,14. 1. Brain Autoimmunity Group, Kids Neuroscience Centre at Kids Research, The Children's Hospital, Westmead, New South Wales. 2. Sydney Medical School, University of Sydney, Sydney, New South Wales. 3. Department of Neurology, Westmead Hospital, Sydney, New South Wales. 4. Save Sight Institute, University of Sydney, Sydney, New South Wales. 5. Department of Neurology, Royal Children's Hospital, Melbourne, Victoria. 6. University Hospital Geelong, Geelong, Victoria. 7. Department of Paediatrics, Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Victoria. 8. Department of Neurology, John Hunter Hospital, Newcastle, New South Wales. 9. Hunter Medical Research Institute, Faculty of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales. 10. Department of Ophthalmology, Westmead Hospital, Sydney, New South Wales. 11. Brain and Mind Centre, University of Sydney, Sydney, New South Wales. 12. Department of Neurology, Concord Repatriation General Hospital, Sydney, New South Wales. 13. TY Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Sydney, New South Wales. 14. Applied Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
Abstract
BACKGROUND AND PURPOSE: Antibodies to myelin oligodendrocyte glycoprotein (MOG) have been identified in both children and adults with demyelination, with a strong association with bilateral or recurrent optic neuritis (ON). However, the full clinical spectrum of this newly described condition is unknown. We sought to describe non-ON inflammatory ophthalmological presentations such as uveitis and optic perineuritis in the context of MOG antibody seropositivity. METHODS: Using a live cell-based assay analysed by flow cytometry, we identified seropositive patients referred for MOG antibody testing in Australasia between 2014 and 2017. We identified four MOG antibody-positive patients with non-ON inflammatory ophthalmological presentations and present their detailed clinical information in this case series. RESULTS: Three patients had uveitis either in association with, or remote from, ON. One patient had optic perineuritis and peripheral ulcerative keratitis. We describe the presentation, examination, investigation findings and clinical course of these four patients. CONCLUSIONS: Recognition of these novel clinical associations may expand the clinical spectrum of MOG antibody-associated presentations. An expedited diagnosis may guide the management of these complex patients.
BACKGROUND AND PURPOSE: Antibodies to myelin oligodendrocyte glycoprotein (MOG) have been identified in both children and adults with demyelination, with a strong association with bilateral or recurrent optic neuritis (ON). However, the full clinical spectrum of this newly described condition is unknown. We sought to describe non-ON inflammatory ophthalmological presentations such as uveitis and optic perineuritis in the context of MOG antibody seropositivity. METHODS: Using a live cell-based assay analysed by flow cytometry, we identified seropositive patients referred for MOG antibody testing in Australasia between 2014 and 2017. We identified four MOG antibody-positive patients with non-ON inflammatory ophthalmological presentations and present their detailed clinical information in this case series. RESULTS: Three patients had uveitis either in association with, or remote from, ON. One patient had optic perineuritis and peripheral ulcerative keratitis. We describe the presentation, examination, investigation findings and clinical course of these four patients. CONCLUSIONS: Recognition of these novel clinical associations may expand the clinical spectrum of MOG antibody-associated presentations. An expedited diagnosis may guide the management of these complex patients.
Authors: Laura Clarke; Simon Arnett; Kate Lilley; Jacky Liao; Sandeep Bhuta; Simon A Broadley Journal: Clin Exp Immunol Date: 2021-07-06 Impact factor: 4.330
Authors: Fiona Tea; Joseph A Lopez; Sudarshini Ramanathan; Vera Merheb; Fiona X Z Lee; Alicia Zou; Deepti Pilli; Ellis Patrick; Anneke van der Walt; Mastura Monif; Esther M Tantsis; Eppie M Yiu; Steve Vucic; Andrew P D Henderson; Anthony Fok; Clare L Fraser; Jeanette Lechner-Scott; Stephen W Reddel; Simon Broadley; Michael H Barnett; David A Brown; Jan D Lunemann; Russell C Dale; Fabienne Brilot Journal: Acta Neuropathol Commun Date: 2019-09-03 Impact factor: 7.801
Authors: Fiona Tea; Deepti Pilli; Sudarshini Ramanathan; Joseph A Lopez; Vera Merheb; Fiona X Z Lee; Alicia Zou; Ganesha Liyanage; Chelsea B Bassett; Selina Thomsen; Stephen W Reddel; Michael H Barnett; David A Brown; Russell C Dale; Fabienne Brilot Journal: Front Immunol Date: 2020-02-06 Impact factor: 7.561